Immuron Limited (AU:IMC) has released an update.
Immuron Limited’s CEO, Steven Lydeamore, is set to host a webinar on August 8, 2024, which will be available live via Zoom and as a recorded copy post-event. The Australian biopharmaceutical company specializes in creating oral antibodies for infectious diseases, with products like Travelan® for travelers’ diarrhea and IMM-529 for recurrent Clostridioides difficile infection showing promising results.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
